Tag Archive for: Yervoy

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

Saturday’s readout, which were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, could position BMS to challenge Merck’s dominant PD-1 blocker Keytruda.

Although BMS did not provide specific data in yesterday’s announcement, the company said the combination regimen induced a “statistically significant and clinically meaningful improvement” in progression-free survival (PFS), compared with the investigator’s choice of chemotherapy.

The series of direct-to-consumer oncology advertisements targeting patients with advanced kidney cancer (renal cell carcinoma) and their caregivers.  

With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.

Today, the company announced that Part A of the Phase III CheckMate -914 which evaluated the two drugs in combination as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.

The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.